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ABSTRACT: Huntington’s disease is a genetic
neurodegenerative disorder. White matter alterations
have recently been identified as a relevant pathophysio-
logical feature of Huntington’s disease, but their etiology
and role in disease pathogenesis and progression remain
unclear. Increasing evidence suggests that white matter
changes in this disorder are attributed to alterations in
myelin-associated biological processes. This review first
discusses evidence from neurochemical studies lending
support to the demyelination hypothesis of Huntington’s
disease, demonstrating aberrant myelination and changes
in oligodendrocytes in the Huntington’s brain. Next, evi-
dence from neuroimaging studies is reviewed, the limita-
tions of the described methodologies are discussed, and
suggested interpretations of findings from published studies
are challenged. Although our understanding of Huntington’s
associated pathological changes in the brain will
increasingly rely on neuroimaging techniques, the
shortcomings of these methodologies must not be
forgotten. Advances in magnetic resonance imaging
techniques and tissue modeling will enable a better
in vivo, longitudinal characterization of the biological
properties of white matter microstructure. This in turn
will facilitate identification of disease-related bio-
markers and the specification of outcome measures in
clinical trials. © 2020 The Authors. Movement Disor-
ders published by Wiley Periodicals, Inc. on behalf of
International Parkinson and Movement Disorder
Society.
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Huntington’s disease (HD) is a genetic neurodegenerative
disorder that leads to debilitating cognitive, psychiatric,
and motor symptoms. The mutation accountable for HD
is an expansion of the cytosine-adenine-guanine (CAG)
repeat within the huntingtin (HTT) gene. A clinical diag-
nosis of symptomatic HD requires the onset of motor
abnormalities such as chorea, motor impersistence (ie,
the inability to sustain simple voluntary movements),
along with the presence of a family history of the dis-
ease.1 Currently, HD cannot be cured, and a research
priority is to increase the understanding of its pathogenesis
and to provide biomarkers for evaluating the efficacy of
targeted therapies.
Although HD pathology is tightly associated with the
degeneration of striatal gray matter (GM),2 during the
past years HD research has identified white matter
(WM) changes as relevant pathophysiological features
of HD.1,3-10 However, despite a subcortical WM vol-
ume loss of 29% to 34% already having been reported
in postmortem HD brains more than 20 years ago,11
the etiology of WM degeneration and its role in disease
pathogenesis and progression remain unclear.
Although some work suggests that WM damage in HD
is secondary to the loss of GM volume in the form of
Wallerian degeneration,11 there is evidence suggesting that
WM aberrations are a feature of HD that occurs indepen-
dent of neuronal cell loss.1,5,8,12-17 Accordingly, WM
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changes are present very early in the disease course, even
in children at risk for HD,18 and in premanifest individ-
uals who are more than 15 years away from symptom
onset.4,17,19 Notably, WM is composed of axons as well
as nonneuronal glia cells, such as myelin-producing oligo-
dendrocytes, and it is unclear whether axons, myelin, or
both are predominantly responsible for the WM loss.7
An increasing body of research suggests that WM
in HD is subject to alterations in myelin-associated bio-
logical processes at the cellular and molecular
levels.13,15,20-24 Myelin is an axon-wrapping, multilay-
ered sheath and is produced by oligodendrocytes. Axon
myelination is vital during brain development and criti-
cal for healthy brain function as it plays a fundamental
role in the regulation of efficiency and speed of
action potential propagation during synaptic transmis-
sion.25,26 Dysfunction in oligodendrocytes and myelin
can slow down or stop otherwise fast axonal transport,
which in turn can result in synaptic loss and eventually
axonal degeneration.27 Furthermore, as myelination
patterns across the brain enable the temporal synchro-
nization of information processing, local demyelination
can disrupt the performance of functional networks.28
The demyelination hypothesis of HD4 suggests that
mutant huntingtin (the protein produced by the
huntingtin gene) leads to premature myelin breakdown
in HD. A dysfunction of oligodendrocytes in turn might
impair the repair of demyelinated axons, leading to
chronic demyelination. Alternatively, as oligodendro-
cytes are the major iron-containing cells of the central
nervous system, it might be that homeostatic increases
in these cells, related to their role in remyelinating
axons, cause significant increases in ferritin iron con-
tent. High ferritin iron is proposed to have toxic effects
and could further contribute to impairments in WM
and myelination.4,29,30
The objective of the present work was to systemati-
cally review the impact of HD pathology on WM
microstructure and to evaluate evidence on the demye-
lination hypothesis,4 which was initially proposed
10 years ago.
To look for relevant articles, we performed a search
in PUBMED and GoogleScholar.com using the follow-
ing keywords: Huntington’s disease, white matter,
white matter microstructure, myelin, myelination, diffu-
sion tensor imaging, magnetic resonance imaging,
mouse models of Huntington’s disease, premanifest,
presymptomatic, symptomatic, oligodendrocytes, iron.
The articles identified were short listed based on their
titles and abstracts. The reference sections of relevant
articles were also used to search for additional relevant
articles. The criteria for inclusion in this review were
the following: studies describing WM differences and
changes in HD mutation carriers either at the pre-
manifest or symptomatic stage and studies on animal
models of HD investigating molecular or cellular
processes linked to WM microstructure or assessing
HD-related changes in brain structure with magnetic
resonance imaging (MRI). A total of 103 studies, publi-
shed between 1973 and 2020, were reviewed; 69 of
these described research involving patients with HD.
WM Impairment in HD: Secondary to,
or Independent of, Neuronal
Degeneration?
WM changes have been reported both in animal models
and in HD human carriers by histopathological postmor-
tem studies11,21,22,31 and MRI studies.4,9,17,22,32-34 These
have shown widespread WM volume loss1,5,6,17,19,33-35
and WM alterations at the microstructural and molecular
levels.4,8,10,14,21,22,33,36-38
The earliest WM alterations are seen in HD human
carriers years before the onset of signs and symptoms
of manifest HD. Prominent areas of damage include the
striatum, the corpus callosum (CC), and posterior WM
tracts.12,34,36,39,40 Furthermore, the severity of WM
changes has been shown to correlate with predicted
time to symptom onset in premanifest patients,1,6,38
with measures of motor dysfunction33 and with cogni-
tive deficits.33,41
Evidence from Neurochemical Studies
This section reviews evidence for molecular and neu-
rochemical changes in oligodendrocyte lineage cells and
myelin sheaths in HD. These changes have been
reported in some human subjects and also in studies of
animal models of HD.
The phenotype exhibited by each animal model of
HD needs to be considered in the context of the dif-
ferent approaches used to generate the respective
model.42 Key distinguishing factors are the genetic
approach and transgene construct used, for example,
the use of full-length or only a fragment of mutant
huntingtin (HTT), the length of the CAG repeat
incorporated into the genome, the expression of the
HD mutation from a transgene versus knock-in of
the mutation into the endogenous HTT locus. In gen-
eral, because knock-in models carry the mutation in
its appropriate genomic and protein contexts, they
are considered as more accurate genetic models of
the human condition compared with transgenic
models.43
Importantly, findings from animal models of HD
need to be considered while keeping in mind the inher-
ent differences between these animal and human
models. Specifically, the equivalent and divergent fea-
tures of the brain for different species need to be under-
stood to ensure that data extrapolation is performed
rationally. For example, when looking at rodent brains,
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the most obvious difference is that these are tiny
(~0.4 g in mice, ~2.0 g in rats), lissencephalic (do not
have sulci or gyri), and have little WM. On the other
hand, the human brain is much larger (approximately
1300 g) and has a readily evident lobular organization,
prominent sulci and gyri, and extensive WM (about
40% of the brain).44
Abnormalities of Oligodendrocyte Lineage Cells
in HD
An increase in oligodendroglia differentiation in neu-
ral progenitor cells was observed during postnatal
development in transgenic HD rats.45 Similarly,
enhanced proliferation of oligodendrocyte precursor
cells was found in adult HdhQ250 mice.22 In addition,
Simmons and colleagues23 reported increased immuno-
staining for ferritin, an iron storage protein that is
mostly found in oligodendrocytes, in the striatum, cor-
tex, and hippocampus of the R6/2 transgenic mouse
model of HD and detectable before any behavioral
abnormalities could be observed. Human postmortem
histopathological studies have also demonstrated an
increase in the density of oligodendrocytes in the stria-
tum of patients with HD compared with healthy con-
trols, years before striatal atrophy or a loss of neurons
occurs.15,20 The increased number of oligodendrocytes
observed suggests the presence of a homeostatic myelin
repair mechanism, aiming to compensate deficits in
myelination that seem to occur in HD.
In contrast, a study using carbon-14 dating
approaches indicated that oligodendrocyte lineage cells
are the most depleted cell types among all nonneuronal
cells in the symptomatic HD brain.46 Furthermore, a
dramatically lower number of mature oligodendrocytes
during the postnatal myelination period has been
shown in the HdhQ250 knock-in mouse model of
HD.22 This evidence suggests that HD might be associ-
ated with a lack of oligodendrocytes, which cannot
repair demyelinated axons. Accordingly, silencing
oligodendroglia-specific mutant-HTT (mHTT) expres-
sion in BACHD mice rescues deficits in the thickness
and compactness of myelin sheaths that otherwise
occur in these mice,3 and expressing mHTT selectively
in the oligodendrocytes of transgenic mice induces
impairments in myelination.21 Overall, the present find-
ings suggest that there is a relationship between the HD
mutation and oligodendrocyte dysfunction.
To summarize, although increased numbers of oligo-
dendrocytes have been observed, their dysfunctionality
may lead to unsuccessful myelination. It is also possible
that the observed increased levels of oligodendrocytes
are helpful at first but eventually lead to toxicity
because of increased iron levels. Both explanations fit
within the demyelination hypothesis4 as they implicate
an increasingly unsuccessful compensation for the
disease-related myelin loss.
Myelin Changes in HD
Reports from human postmortem studies have dem-
onstrated a striking breakdown of myelin in the HD
brain.47 In addition, some studies on animal models
have indirectly demonstrated impairments in develop-
mental myelination in HD: these have shown that the
expression of a mutant huntingtin transgene in cells
and in R6/2 transgenic mice leads to reduced activity in
the cholesterol biosynthesis pathway that in turn results
in lower levels of newly synthesized cholesterol and its
intermediates,48,49 which are essential for the synthesis
of myelin.50
Electron microscopy investigations have reported
thinner myelin sheaths, as reflected by higher g-ratios
(the ratio of the inner axonal diameter to the outer
diameter), in transgenic BACHD rats and in the
HdhQ250 knock-in mouse model.22,24 HD myelin
changes might either represent a breakdown of
myelin into fragments because of toxicity or thinner
myelin sheaths because of a developmental dysfunction
in myelination mechanisms. Consistent with the latter,
alterations in myelin sheaths are paralleled by the
reduced expression of myelin-related genes such as
myelin basic protein (MBP) and myelin oligodendrocyte
glycoprotein (MOG) in transgenic R6/2 and HdhQ250
knock-in mice.22,51,52 Reduced levels of MBP and
MOG in brain regions known to be affected by HD
throughout the critical postnatal myelination stage, and
significantly fewer myelinated axons, have been
reported in knock-in HdhQ250 mice.22 The reduction
in myelin proteins may be attributed to a decreased
expression of myelin regulatory factor (MRF), a tran-
scription factor that controls the expression of myelin-
related proteins.22 Moreover, abnormalities in myelin
sheaths and myelin-related gene transcripts in YAC128
transgenic mice are evident well before any striatal neu-
ronal loss can be detected.24 These findings imply that
a dysregulation of the temporal profile of myelination
might underlie WM abnormalities and that disordered
myelination during the postnatal period might consti-
tute an important early pathogenic event in HD.22
Evidence from Imaging Studies
Neuroimaging techniques enable the assessment of
brain structure and function in vivo and allow the
understanding of disease pathology over time. How-
ever, as much of our understanding of HD pathology
will increasingly rely on advanced neuroimaging tech-
niques, it is important to bare in mind the limitations of
these approaches. Table 1 provides a summary of MRI
results observed in patients with HD in studies dis-
cussed in this review. Interpretations proposed by the
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respective authors and alternative explanations found
in the literature for such changes are reported. Table 2
summarizes MRI studies reporting WM changes in HD
animal models.
Structural neuroimaging studies in animal models of
HD and in HD carriers have shown that WM atrophy
can be found across several WM areas, including the
CC, the anterior commissure, internal and external cap-
sules, and the cingulum. Furthermore, they suggest that
these WM changes happen very early in the disease
course.6,12,17,19,53 Importantly, deficits in brain growth
and WM changes are already found in children at risk
for HD,18,54 further pointing to a neurodevelopmental
effect of mHTT.
Some studies have suggested that WM is more
affected than GM in the HD brain. For example,
Tabrizi and colleagues35 showed that the rate of change
of WM volume over 24 months was greater than that
of GM in patients with premanifest and early HD.35
Specifically, individuals carrying the mHTT gene who
were far away from clinical diagnosis showed WM loss
only around the striatum and within the CC and poste-
rior WM tracts, whereas those close to clinical diagno-
sis and patients with symptomatic HD showed
extensive WM loss across the whole brain. Loss of WM
volume during this time period ranged between 2% in
HD carriers more than 10 years away from disease
onset and 4% in patients with early HD. Effect sizes
for atrophy rates between early HD participants and
healthy controls were larger in WM (1.70, 1.40–2.08)
than in GM. In addition, a 2-year longitudinal study
found that, when controlling for normal age-related
variations, brain atrophy of premanifest patients was
more pronounced in WM than in striatal GM.19 Simi-
larly, in another patient cohort, WM volume was drasti-
cally reduced in premanifest participants when compared
with controls (35.3 ± 2.5 mL vs. 37.7 ± 2.2 mL), whereas
no significant differences were observed for GM
volumes.6
The findings summarized previously suggest that there
might be a dissociation between neurodegenerative pro-
cesses that happen in GM and WM aberrations in
HD. Furthermore, the temporal pattern of reported WM
changes suggests that WM impairment in HD unlikely
reflects solely a secondary result of neuronal cell death in
GM and may instead represent an independent factor of
HD pathology. Evidence for a link between GM and
WM changes comes from studies that show significant
atrophy of the cortical mantle of patients with HD both
cross-sectionally55-58 and longitudinally,53 suggesting
that WM volume loss may be a consequence of the with-
drawal of axons projecting from cortical neurons.
These studies have relied on measures of WM vol-
umes. However, WM volume loss as quantified using
structural MRI is a rather unspecific marker of disease
stage and progression as it is not sensitive to changes in
microstructure. This makes it hard to capture differen-
tial effects across the various stages of the disease.59 As
such, reductions in WM volume observed in structural
neuroimaging studies can be the consequence of several
factors, including a decrease in the number of axons
because of Wallerian degeneration,53,55-58 a decrease in
axon myelination,6,60 or a combination of both.
New MRI methods allow us to move beyond tradi-
tional macrostructural volumetric methods and provide
more in-depth information about tissue integrity and
organization at the microstructural and biochemical
levels.
To date, most neuroimaging studies of WM micro-
structure have used diffusion tensor MRI (DT-MRI)61
to quantify tissue properties. This technique character-
izes the 3-dimensional diffusion of water as a function
of spatial location, and it is based on the differential
diffusion of water molecules depending on tissue type
and architecture.62 For example, the molecular diffu-
sion rate (mean diffusivity), the directional preference
of diffusion (fractional anisotropy [FA]), the diffusion
rate along the main axis of diffusion (axial diffusivity
TABLE 1. MRI changes observed in the reviewed in vivo studies in patients with HD: interpretations proposed by the
respective authors and alternative explanations found in the literature for such changes
Reported Change Proposed Interpretation Possible Alternative Interpretation
Reduced WM volume Decreased number of axons attributed to
Wallerian degeneration50-54
Decrease in axon myelination6,5
Reduced axial diffusivity Axonal degeneration2 Inflammation, nonuniform axonal oedema, beads, varicosities parallel to
the axon segments, microglia/macrophage activation100
Increased radial diffusivity Demyelination2,9,18,60,69,70 Less coherent alignment of fibers, more crossing fibers from other
bundles, lower density or less myelination of the fibers, or a
combination of any or all these factors101
Reductions in the neurite
density index
Decrease in axonal density76 Reduced MRI signal because of demyelination102
Reductions in MPF Demyelination59 Changes in cells and water content attributed to inflammation79,83
Shortened T2 Increased ferritin levels86,89 Remyelination103
MPF, macromolecular proton fraction; MRI, magnetic resonance imaging; WM, white matter.
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[AD]), and the rate of diffusion in the transverse direc-
tion (radial diffusivity [RD]) can be inferred.
Some evidence from DT-MRI studies suggests that
WM aberrations in HD are a consequence of Wallerian
axonal degeneration. For example, it has been shown
that WM changes correlate with reductions in cerebral
GM density.9,12 Similarly, a DT-MRI study suggested
that WM changes in HD are a consequence of axonal
injury rather than demyelinating mechanisms based on
the observation of greater changes in AD, as compared
to RD changes, in the brains of patients with HD.2
On the other hand, there are several DT-MRI studies
that have suggested a role for myelin in HD pathol-
ogy.4,9,12,14,63,64 These studies parallel findings from
postmortem, histopathological studies in patients with
HD.47 First, insufficient myelination was suggested to
be present in children at risk of HD, as they showed
increased RD in the external capsule. Specifically, the
authors hypothesized that this increase may reflect an
impairment in myelin integrity because of a dysfunction
in the trophic support mechanisms usually carried out
by normal HTT. This in turn is suggested to affect mye-
lin integrity by hindering the production and mainte-
nance of large lipid membranes.18 In addition, Di Paola
and colleagues64 suggested that demyelination is
present in the premanifest HD brain, whereas both
myelin breakdown and axonal damage are present in
manifest HD. This proposal was based on the observa-
tion of decreased FA and increased RD in the isthmus of
the CC of premanifest patients compared with age-
matched and sex-matched controls in the absence of any
changes in AD.64 On the other hand, they reported both
increased RD and decreased AD in the CC of patients
with manifest HD compared with matched controls.
Similarly, Rosas and colleagues9 showed increased RD
in the WM of patients with premanifest HD, which cor-
related with impaired performance on neuropsychologi-
cal tests and was proposed to reflect early deficits in
myelin. Moreover, they suggested that axonal pathology,
as shown by changes in AD, is present only later in the
disease course.
All of the aforementioned interpretations are built on
the assumption of a direct correspondence between a
specific microstructural property of WM and variations
in DT-MRI metrics. However, although DT-MRI met-
rics are often regarded as probes of WM microstruc-
ture, these indexes do not tap specifically onto
biological subcomponents of WM microstructure65 in
that the tensor measured in the DT-MRI model is an
average of all the cellular compartments within a
TABLE 2. Summary of reviewed MRI studies of HD animal models
Species/Model
MRI Technique
(In Vivo/Ex Vivo) Findings
Neurochemical
Validation Reference
R6/2 mice DT-MRI (ex vivo) FA reductions in genu and splenium of the corpus callosum. Yes 49
YAC128 mice Structural MRI (ex vivo) Progressive loss of WM volume.
Corpus callosum, anterior commissure, and fimbria are among




FA reductions in the anterior commissure, corpus callosum,
internal capsule, and external capsule, from 1.5 months of





FA reductions in the anterior corpus callosum, the cingulum,
and the external capsule at 12 months of age.
Yes 23
TgHD rats DT-MRI and
PET (in vivo)
Increased MD in HD rats at 12 months of age, compared with
earlier time points; this parameter remained constant in WT
animals.
Age-related RD decreases at 6 months of age in HD animals but
only at 12 months in WT animals.
Yes 94
TgHD rats Diffusion kurtosis
imaging (in vivo)
Neuronal development in HD rat pups occurs differently
compared with controls: higher MD values at P15 but lower
MD and AD values at P30 in external capsule.
Yes 48
rHD1 rhesus monkeys DT-MRI
(in vivo)
Widespread WM changes in FA, MD, and RD.
HD monkeys reached the maximal FA value earlier (22.7 ± 4.8
months) compared with controls (47.8 ± 11.7), revealing an
arrest of WM maturation in the HD group; across ages, HD
monkeys had significantly lower maximal FA values in all
areas investigated.
Significantly higher minimum RD values of HD monkeys in the
striatal bundle.
No 31
WM disturbance appears to be an early pathogenic event. An altered developmental trajectory of WM is suggested by asymmetric age-related changes of MRI
metrics between HD models and wild types.
AD, axial diffusivity; DT-MRI, diffusion-weighted magnetic resonance imaging; FA, fractional anisotropy; HD, Huntington’s disease; MD, mean diffusivity; MRI,
magnetic resonance imaging; PET, positron emission tomography; RD, radial diffusivity; WM, white matter.
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specific voxel.66 It is therefore very hard to interpret
changes in DT-MRI metrics in terms of changes in
specific microstructural properties.67 Very different con-
figurations of, for example, axonal packing, axonal
size, and myelination may generate very similar out-
come measures. Furthermore, RD and AD become diffi-
cult to interpret when multiple fiber orientations are
present within a voxel, such as at fiber bundle
crossings,68 and this situation affects between one and
two thirds of the voxels in a human brain.69,70
Specifically, these interpretations are based on the
assumption that AD and RD are uniquely sensitive to
axonal degeneration and demyelination, respectively.71-
77 Such inferences are based on one study on Shiverer
mice, where changes in myelin content were linked to
increased RD, but unchanged AD.73 However, an
increase in RD might not necessarily correspond to
myelin loss; rather, it can have multiple meanings,
including axonal loss.67 Furthermore, in regions of
crossing fibers, increased RD within a specific tract
could be attributed to a less coherent alignment of
fibers, more crossing fibers from other bundles, lower
density or less myelination of the fibers, or a combina-
tion of any or all of these factors.67,68
Biophysical models of diffusion MRI, such as neurite
orientation and dispersion density imaging78 and the com-
posite hindered and restricted model of diffusion66 model
compartment-specific water diffusion to dissociate hin-
dered extracellular and restricted intracellular diffusion
properties of WM and should therefore provide a more
biologically specific characterization of WM microstruc-
tural organization within the neural system.79
Zhang and colleagues80 used neurite orientation and
dispersion density imaging to examine WM pathology
in patients with premanifest HD. They reported wide-
spread reductions in the neurite density index—a proxy
of axonal density—in tracts including the CC and in
WM surrounding the basal ganglia of patients with
presymptomatic HD. Importantly, axonal density
reductions in callosal regions predicted clinical markers
of disease progression. Finally, increased coherence of
axonal organization, as suggested by a smaller orienta-
tion dispersion index, was shown in patients with HD
in tracts surrounding the basal ganglia and in the inter-
nal and external capsules, suggesting the presence of
possible compensatory pruning of the axons in WM
regions. Nevertheless, the estimation of specific tissue
quantities from these models requires simplifying
assumptions whose accuracy and generality, in the HD
brain especially, are unknown. These techniques indeed
still represent a relatively simple approach to modeling
neural tissue and therefore cannot fully characterize
pathological changes in WM microstructure.81
Quantitative magnetization transfer (qMT) imaging has
enabled greater sensitivity to myelin content in WM.82
This method models the exchange rate between
macromolecular protons and protons in surrounding tis-
sue water when macromolecular protons are subjected to
a radiofrequency pulse with a frequency that is off-
resonance for protons in free water.83 One of the outcome
measures of qMT, the macromolecular proton fraction
(MPF), has been shown to reflect demyelination in
Shiverer mice and puppies,82,84 to be sensitive to dys-
myelination processes in multiple sclerosis patients,85 and
to reflect myelin content of WM in postmortem studies of
brains with multiple sclerosis.86 A study by Bourbon-Teles
and colleagues63 used diffusion tensor imaging and qMT
to investigate HD-related effects on WM pathways of the
basal ganglia and motor systems. Specifically, the study
compared patients with HD (24 manifest and 1 pre-
manifest) to age-matched and sex-matched healthy con-
trols. Although the patients with HD relative to controls
exhibited significant reductions in an MPF component
with high loadings of MPF in all WM regions, no differ-
ences were observed for components with loadings of
AD, RD, or FA. The authors concluded that this pattern
of results was consistent with a myelin impairment in
HD. Interestingly, the MPF component score of the 1 pre-
manifest individual in the study differed more than 3 times
the standard deviation from the control mean. This obser-
vation suggests that MPF might already be reduced prior
to disease onset and that MPF should be assessed as an
early disease biomarker in a group of premanifest gene
carriers.63
Although MPF is sensitive to WM myelin, this metric
can also be affected by changes in cells and water content
because of inflammation.87 Odrobina and colleagues,88
for example, measured MPF ex vivo in a demyelinated rat
sciatic nerve and confirmed its correlation with myelin
content, but also noted the difficulty of separating demye-
lination from inflammation by qMT alone. Nevertheless,
although in manifest HD it is likely that inflammation
goes hand in hand with myelin breakdown,89 a recent
cerebrospinal fluid biomarker study found no evidence of
neuroinflammation in early-manifest HD.90 It is therefore
plausible that changes in the MPF observed in this study
were a reflection of aberrant myelination in these patients.
Human MRI studies have also shown that HD is
associated with changes in iron levels across several
brain areas.4,23,29,30,91 Tissue iron can be measured by
MRI in vivo through its effect on transverse relaxation
times (T2). Ferritin (the storage protein of iron) has
been shown to strongly affect the MRI signal and
markedly shorten T2 both in vitro and in vivo.92,93
Increased ferritin levels are already present in the pre-
manifest stage of HD.91,94 As oligodendrocytes are the
major iron-containing cells in the adult central ner-
vous system,95 the increased density of oligodendro-
cytes in HD that was demonstrated in mice
models22,23 should result in significant increases in
iron and ferritin content in the HD brain. Evidence for
increases in MRI-based iron measures in HD further
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supports the suggestion for a homeostatic increase in
oligodendrocytes as an active repair mechanism in
patients with premanifest HD.
Early and heavily myelinated fibers are the most sus-
ceptible to myelin breakdown in HD,4 with WM degen-
eration starting in the caudate and putamen striatum
structures and then spreading in a predictable, bilateral,
and symmetric pattern to involve other earlier
myelinating regions. In turn, later myelinating regions
such as the medial temporal lobe are left much less
affected.29,96 This is consistent with neuroimaging evi-
dence that the earliest WM changes in HD are seen
before disease onset in early myelinating regions such
as around the striatum, within the CC, and in posterior
WM tracts.12,34,36,39 The spatial pattern of pathology is
in contrast with the “last-in-first-out” hypothesis that
was proposed for degenerative processes of normal
brain aging,97 which postulates that later myelinating
fibers are more vulnerable to insult in later life com-
pared with earlier myelinating fibers.
Consistent with the suggestion of a dissociation
between early and late myelinating regions in WM
impairment in HD,4 Bartzokis and colleagues4 showed
decreased ferritin iron levels in HD in the genu of the
CC and frontal WM (late-myelinating regions) and
increased ferritin iron levels in the basal ganglia
(an early myelinating region). Decreased iron levels
in late-myelinating regions are proposed to be attrib-
uted to suboptimal iron availability because of a redis-
tribution of iron toward earlier myelinating regions.
Furthermore, although remyelination processes may
successfully compensate for myelin loss during the pre-
manifest HD stage, these may start failing in later years,
likely explaining evidence of decreases in iron content
found between the patients with premanifest and symp-
tomatic HD.12,91
Discussion and Future Directions
In the present review, we discussed evidence of WM
abnormalities in HD. Although this disease has been
tightly linked to striatal GM degeneration, an accumu-
lating body of evidence suggests that alterations in WM
microstructure are present early in HD
progression,1,6,17,19,53 even in children at risk for
HD,18,54 and possibly even before any changes can be
detected within the striatum.19 This implies that WM
disturbances might independently contribute to HD
pathogenesis4,17,19 and that, rather than being second-
ary to axonal insult in the form of Wallerian
degeneration,2,80 they might be a direct result of myelin
and oligodendrocytes disturbance.4,14,15,20,98 Demyelin-
ation has been associated with severe disabilities in
many developmental, psychiatric, and neurodegenera-
tive diseases.26 Therefore, it is possible that also in HD,
myelin loss, which leads to altered axonal conduction
and axonal damage, may be directly responsible for
some of the clinical symptoms. Furthermore, oligoden-
drocyte dysfunction early in the disease course may
impair the processes of remyelination and myelin
repair.4
A number of studies on HD animal models22,32,51,52,99
have lent support to the demyelination hypothesis of
HD.4 Importantly, it is essential to consider these find-
ings while always keeping in mind the equivalent and
divergent features of the brain of different species. Never-
theless, studies on human HD carriers also suggest the
presence of myelin dysfunction.4,9,14,63,64 However, most
studies assessing WM changes in vivo have employed dif-
fusion tensor imaging–MRI based metrics to quantify
these alterations, even though these indexes do not tap
specifically into biological subcomponents of WMmicro-
structure.65,100,101 Recent advances in MRI techniques
and tissue modeling enable a better characterization of
the biological properties of WM microstructure and
allow more specific monitoring of changes in these prop-
erties, both longitudinally and noninvasively.102 Longitu-
dinal studies designed to relate specific microstructural
changes to the genesis of pathology, while controlling for
individual differences such as the impact of environmen-
tal factors, will prove particularly useful. Although it is
evident that our understanding of the HD brain will
increasingly rely on advanced MRI techniques, this reli-
ance highlights the need to remember and address the
shortcomings of these methodologies.
The identification of early changes in the brain
WM microstructure in patients with HD is of funda-
mental importance as it allows insight into disease
pathogenesis and progression and, further, might
prove useful for the identification of disease-related
biomarkers and in measuring outcomes of clinical tri-
als. In many neurodegenerative diseases such as
Alzheimer’s and Parkinson’s diseases, myelin distur-
bance starts before other pathological changes are
evident.4,103 Similarly, in HD, critical pathogenic
events might be present prior to neuronal death, and
there might be a decades-long period in which thera-
peutic intervention could change the course of the dis-
ease, before clinical evidence, such as behavioral,
cognitive, and motor decrements, appear. Nonethe-
less, in vivo investigation of demyelination in patients
with premanifest and symptomatic HD remains rela-
tively unexplored when compared with other neuro-
degenerative diseases such as multiple sclerosis, and
very little research has been carried out on the HD
brain using these approaches.
To conclude, we reviewed the evidence that impli-
cates WM aberrations and in particular impaired mye-
lin and oligodendrocytes in HD pathology and suggests
that these could constitute important targets for the
study and early treatment of HD.
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